In the EU, rare diseases that are also life-threatening or chronically debilitating with a low prevalence and a high level of complexity are defined as orphan diseases.
Biological medicines are far more complex and usually much bigger than chemical medicines, which
There is no common European consensus on how to reward healthcare innovation.
Manufacturing biological medicines is generally more complex than the production of traditional (
The biotech industry proposes the development of shared European standards for HTAs to ensure the
Innovative medicines generally benefit from a certain period of intellectual property protection